Awakn Life Sciences Corp.
AWKN
CNSX
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -66.25% | -47.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -66.25% | -47.37% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -66.25% | -47.37% | |||
| SG&A Expenses | -26.25% | -15.95% | |||
| Depreciation & Amortization | -2.94% | -2.86% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.62% | 7.89% | |||
| Operating Income | 18.74% | -10.10% | |||
| Income Before Tax | -4.51% | 34.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.51% | 34.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.51% | 34.35% | |||
| EBIT | 18.74% | -10.10% | |||
| EBITDA | 18.87% | -10.21% | |||
| EPS Basic | -1.28% | 23.53% | |||
| Normalized Basic EPS | 0.00% | 23.44% | |||
| EPS Diluted | -1.28% | 23.53% | |||
| Normalized Diluted EPS | 0.00% | 23.44% | |||
| Average Basic Shares Outstanding | 3.41% | -13.62% | |||
| Average Diluted Shares Outstanding | 3.41% | -13.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||